Search

Displaying results 4311 - 4320 of 9129 in total
  1. Drug

    Testolactone

    go.drugbank.com/drugs/DB00894
    ApprovedWithdrawn

    An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.

  2. Drug

    Methazolamide

    go.drugbank.com/drugs/DB00703
    Approved

    A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.

  3. Drug

    Alcuronium

    go.drugbank.com/drugs/DB13648
    Experimental

    A non-depolarizing skeletal muscle relaxant similar to [tubocurarine]. It is used as an anesthesia adjuvant.

  4. Drug

    Enviomycin

    go.drugbank.com/drugs/DB08993
    Experimental

    It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.

  5. Drug

    Dimenoxadol

    go.drugbank.com/drugs/DB01461
    ExperimentalIllicit

    In the United States it is classified as a Schedule I controlled drug. … Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative.

  6. Drug

    Mersalyl

    go.drugbank.com/drugs/DB09338
    Experimental

    Mersalyl is the sodium salt form of mersalyl acid, a mercurial diuretic. It is an outdated drug, and its approval has been discontinued by the FDA. … The sodium salt of a mercury-containing derivative of salicylamide, was formerly used (often in combination with theophylline) to treat edema, due to its powerful diuretic properties [L1577].

  7. Drug

    AMY-101

    go.drugbank.com/drugs/DB14803
    Investigational

    AMY-101, also known as compstatin 40, is a peptidic inhibitor of the central complement component C3. … AMY-101 is under investigation in clinical trial NCT03694444 (A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis).

    Synonyms: AMY 101
  8. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013. … A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024.

    Categories: Endothelin A Receptor Antagonists
  9. Drug

    OPC-14523

    go.drugbank.com/drugs/DB05422
    Experimental

    OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.

  10. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]